Andy Plump
Tracked across 1 events · 21 articles · First seen Aug 05, 2026 · Last active Aug 19, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Regulatory
The U.S. United States — Food and Drug Administration (FDA) approved Takeda Pharmaceutical Company's Orzeyful (oveporexton) as the first oral orexin receptor 2 agonist for the treatment of narcolepsy type 1 (NT1) in adults. This…
Impact: As Takeda's president of R&D, Andy Plump commented on the approval, emphasizing the significance of orexin as a therapeutic pathway and Takeda's commitment to developing this class of medicines.
Aug 05, 2026 · 21 articles
ERGEN INTELLIGENCE
Track Andy Plump live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard